**Core tip:** Colorectal cancer (CRC) is one of the most prevalent malignancies in the world. CRC-associated morbidity and mortality is continuously increasing, in part due to a lack of early detection. The main aim of this article is the brief description of the basic screening modalities and their efficacy for CRC detection, the process of colorectal carcinogenesis and how the molecular pathways of CRC (focusing on epigenetic modifications) influence the clinical application of new blood-based biomarkers such as circDNA. Then we will focus on the most recent findings concerning the studies on circDNA, mainly related to DNA methylation and the challenges for validation and globally implementation of this emergent technology.

INTRODUCTION
============

Colorectal cancer (CRC) is the most common malignancy presented in gastrointestinal (GI) tract and the third most frequent cancer globally, with an incidence approximately approaching 1.5 million cases per year\[[@B1],[@B2]\]. Likewise, it is considered that over 600000 deaths occur each year by neoplasms of the large bowel making them, the third commonest cause of cancer-related deaths\[[@B2]\]. It is thought that the gradual adoption of Westernized lifestyle and dietary habits by the majority of the countries in association with aging of the population are responsible for the increase in morbidity and mortality rates from CRC. This is in accordance with the World Health Organization which estimates that a substantial increase in the number of newly diagnosed CRC cases and a 80% rise in deaths from CRC are expected by 2030\[[@B3]\]. It should also be pointed out that colorectal adenocarcinomas are distinctive for their relatively fast progression and late clinical presentation, characteristics that are fairly preventable if identified at an early stage. Nevertheless, the currently available screening tests for the early detection of CRC need improvement enough in order to increase their cost-effective status. Thus, it is conceivable that, there is a significant interest in using noninvasive blood biomarkers which could be of low cost and high sensitivity and specificity to help reduce the predicted surge in the incidence of CRC by identification and removal of a larger number of polyps that potentially could lead to CRC over time\[[@B3]\]. These biomarkers are designed to detect molecular indicators in the plasma or serum such as DNA, RNA or protein in order to expand the existing list of CRC screening modalities\[[@B4]\].

Εpigenetic phenomena contribute to colorectal neoplasia\[[@B5]\]. This term refers to the mechanisms that alter gene expression without changing their DNA sequence. Epigenetic phenomena may include DNA methylation, histone modification and chromatin regulation through non-coding RNAs (microRNAS, incRNAs, *etc*.)\[[@B6]\]. Since DNA methylation and DNA mutations detected in tumor cells, it is reasonable to assume that these alterations are reflected in circDNA released from neoplastic tissue into blood circulation. Testing for circDNA in the peripheral blood could serve as an important candidate biomarker for the detection of CRC at early stages. An existing paradigm of commercial blood test for CRC detection in the circDNA is the monitoring of methylation of the septin 9 gene (*SEPT9*) promoter region.

Therefore, the aim of this article is the brief description of the basic screening modalities and their efficacy for CRC detection, the process of colorectal carcinogenesis and how the molecular pathways of CRC (focusing on epigenetic modifications) influence the clinical application of new blood-based biomarkers such as circDNA. Then we will focus on the most recent findings concerning the studies on circDNA, mainly related to DNA methylation and the challenges for validation and globally implementation of this emergent technology.

EXISTING SCREENING MODALITIES TO CRC
====================================

Screening modalities
--------------------

There are various strategies for screening nowadays; the most accepted being the colonoscopy, and the combination of sigmoidoscopy and fecal occult blood test (FOBT). The high sensitivity and specificity has established the colonoscopy the cornerstone for the early identification of colonic malignancies in the average-risk population\[[@B7],[@B8]\]. There are some drawbacks that limit the desired wide acceptance. As an invasive examination, complications may be unavoidable, the most common being cardiovascular events during the procedure and the post-polypectomy bleeding and perforation\[[@B7]\]. Other disadvantages could be a significant miss rate of lesions even for large colonic abnormalities, its high cost and the low acceptance level by the population\[[@B9]\].

Compared to colonoscopy, sigmoidoscopy has quite few disadvantages due to low cost, less preparation time and no need for sedation\[[@B10]\]. The main problem is the ability to detect only the lesions of distal colon making the decision of performing colonoscopy a subject for controversy even to date.

The third and most frequently applied screening test is FOBT\[[@B11]\]. Although these tests are easier to perform than colonoscopy or sigmoidoscopy, they are associated with false positive and false negative results due to diet, other conditions like colitis and hemorrhoids and the effect of temperature on the samples\[[@B12]\]. Moreover, FOBT cannot be used as solo screening test, as a positive results lead to colonoscopy performance\[[@B13]\].

Thus, there is an emergent need for new screening tests such as blood-based test which could detect CRC earlier, increase patient participation with minimal risks, costs, and false positive and negative results.

MOLECULAR PATHWAYS IN CRC AND DNA METHYLATION
=============================================

CRC molecular pathways
----------------------

Colorectal cancer is a multifarious disease. The comprehension of the molecular pathways involved in its development, will help to optimize the screening procedure based on distinctive pathologic and molecular features of the malignancies. Three basic pathways of colorectal carcinogenesis have been recognized since 1990 that is, Chromosomal Instability (CIN), Microsatellite Instability (MSI) and CpG island methylator phenotype (CIMP) pathway\[[@B14]\].

Chromosomal instability, also entitled "the suppressor pathway", was first introduced in 1990 by Fearon et al\[[@B14]\] and is the most frequent etiology for gene alteration in colorectal neoplasia. Its main characteristic is the modification of whole chromosome or some of its regions, affecting important genes leading to carcinogenesis. These genomic defects provoke suppressor genes inactivation as Deleted in Colon Carcinoma (*DCC*), SMAD family member 2 (*SMAD2*), SMAD family member 4 (*SMAD4*), Adenomatosis polyposis coli (*APC*) and tumor protein p53 (*TP53*) and oncogene activation such as the human homolog of the Kirsten rat sarcoma-2 virus oncogene (*KRAS*)\[[@B15]\]. The accumulation of these modifications seems to play the most crucial role for cancer to develop and not the sequence of their presentation as once considered. The second model which involved in normal intestinal mucosa transformation to malignancy is the microsatellite instability. MSI is another type of genomic instability which refers to deletions or insertions of a few nucleotides in genes responsible for repair during DNA replication, the DNA mismatch repair (MMR) genes\[[@B16]\]. This aberrant genomic region mainly segregates in repetitive DNA nucleotide unit (microsatellites) throughout the genome resulting in the inactivation of MMR genes (*i.e*., *MSH2, MLH1, MSH6, PMS1-2, MLH3, MSH3, ExoI*). It is well-known that this route of carcinogenesis is involved in Lynch syndrome and for a notable proportion of sporadic CRC (15%-20%)\[[@B17]\]. The third model involved in the CRC development and progression, is CIMP which refers to the presence of simultaneous hypermethylation of multiple genes. It belongs to the epigenetic mechanisms leading to silence gene function after methylation at the 5'-CG-3'(CpG) dinucleotide in the promoter region of many genes (*APC, MCC, MLH1, MGMT*), resulting therefore, in inactivation of tumor suppressor genes\[[@B18]\]. CIMP is accountable for 15%-20% of sporadic CRC and according to the study of Jass\[[@B19]\], we are able to classify CRC according to the presence of MSI and CIMP as Figure [1](#F1){ref-type="fig"} shows.

![Molecular classification of colorectal cancer. The figure shows the different molecular profile and clinic-histopathological characteristics of each classification. CIMP: CpG island methylator phenotype; MSI: Microsatellite instability; MS: Microsatellite stability; CRC: Colorectal cancer; CIN: Chromosomal instability; HNPCC: Hereditary nonpolyposis colorectal cancer; MGMT: O-6-methylguanine-DNAmethyltransferase; BRAF: v-raf murine sarcoma viral oncogene homologe B1; MLH1: MutL homolog 1; KRAS: Kirsten rat sarcoma 2 viral oncogene homolog; APC: Adenomatosis polyposis coli; TP53: Tumor protein p53.](WJGO-9-142-g001){#F1}

DNA methylation and its role in CRC carcinogenesis
--------------------------------------------------

DNA methylation mainly occurs in specific parts of the genome called, as we have seen previously, CpG islands. Considering the stability of DNA methylation compared to mutations, we may presume that methylation is a favorable area for biomarker exploration.

The concept that genome methylation may play a critical role in specific steps in the CRC carcinogenesis has been expressed in 1983 by Feinberg and Vogelstein\[[@B20]\] who showed that at early stages of CRC there is a DNA hypomethylation, mainly located at CpG islands. They also demonstrated that this loss of methylation was combined by hypermethylation and inactivation of tumor suppressor or DNA repair genes\[[@B21]\]. This epigenetic modification has recently been associated with the normal mucosa-aberrant crypt focus (ACF)-adenoma-carcinoma sequence, playing an important role in CRC development\[[@B22]\]. Consequently, DNA methylation appears to be one of the cornerstones of carcinogenesis because it occurs at the first steps of CRC process; involves CIMP pathway with MSI, as hypermethylation of MMR genes results in MSI sporadic CRC; through CIMP, it has been linked with CIN in colon malignancy (promoter methylation of *GATA4*, *GATA5*, *p16* resulted in chromosomal loss or gain); and finally it is implicated in each of these paths through many abnormally methylated genes as recently studies have revealed\[[@B23]-[@B28]\] (Figure [2](#F2){ref-type="fig"}). The design of genetic and epigenetic biomarkers, especially those related to detection of aberrant methylated genes able to offer the maximum coverage of intestinal neoplasia, seems to be a reasonable approach. Accordingly, several studies have been performed the last decade, for the potential use of DNA markers in different biologic fluids as strategies for colorectal carcinoma early detection\[[@B29]\].

![The figure exhibits the most frequent methylated genes/loci involved in step-by-step adenoma-carcinoma process in the context of colorectal cancer development. SFRP1: Secreted frizzled-related protein 1; CRABP1: Cellular retinoic acid binding protein 2; RUNX3: Runt-related transcription factor 3; CDH13: Cadherin 13; SLC5A8: Sodium solute symporter family 5 member 8; MINT1: Methylated in tumor locus 1; WNT5A: Wingless-type MMTV integration site family, member 5A; p14: Tumor protein 14; HLTF: Helicase-like transcription factor; ITGA4: Integrin, alpha 4; ESR1: Estrogen receptor 1; CDKN2A/p16: Cyclin-dependent kinase inhibitor 2A; CDH1: E-cadherin; CXCL12: Chemokine (C-X-C) ligand 12; ID4: Inhibitor of DNA binding 4; IRF8: Interferon regulatory factor 8; TIMP3: Tissue inhibitor of metalloproteinase 3; MGMT: O-6-methylguanine-DNAmethyltransferase; hMLH1: MutL homolog 1.](WJGO-9-142-g002){#F2}

CELL-FREE CIRCULATING DNA AS A BLOOD-BASED BIOMARKER
====================================================

Mandel and Metais\[[@B30]\] in 1948, were the pioneers who discovered the existence of cell-free nucleic acids (cfNAs) in blood, leading to ''discrimination'' of affected patients from healthy controls, even though the first reported presence of cfNAs was in 1869\[[@B31]\]. Since then, several studies have been made, especially related to cancer pathogenesis, showing that malignant-nucleic acids could be present in different ''body fluids'' (*i.e*., stool, blood, urine). Therefore, it was a matter of time the establishment of the potential advantages using cfNA as noninvasive neoplasia detection\[[@B32],[@B33]\]. The first report referring to detection of ''abnormal'' cfNAs in CRC patients took place in 1992, when Vogelstein et al\[[@B34]\] discovered *KRAS* gene mutation in stools samples of CRC-affected individuals. Since then, a great number of studies have performed evaluating other than *KRAS*, genome modifications directly expressed by cfNAs. These modifications are characterized mainly by analysis of high mutation frequency genes (*KRAS*, *TP53*, and *APC*), MSI, Loss of Heterozygosity (LOH), DNA, and microRNA methylation changes. Except the latter one, all the others are key factors for colorectal carcinogenesis which could expressed by increased circDNA concentrations in blood of CRC patients compared with healthy controls, first mentioned by Leon et al\[[@B35]\] in 1977, followed by many other studies\[[@B35]-[@B37]\].

Thus, since circDNA in blood reflects significant genome alterations emerging during CRC carcinogenesis, it could be used systematically as a potential biomarker for early detection of colonic malignant tumors, especially after the recent advances in next generation sequencing (NGS) technology\[[@B38]\]. Here follows a discussion of methods to detect circDNA-based markers in blood and the studies focusing on description of these markers namely, aberrant DNA methylation and mutations, microsatellite alterations, DNA modifications in mitochondria, integrity and quantification of DNA.

Methods to detect methylation-related circDNA markers in blood
--------------------------------------------------------------

Methodologies suitable to investigate and detect in serum or plasma frequently methylated genomic regions, offering high detection rate is more than an appealing aim. These ideal markers should have low levels of background methylation so as to avoid the decreased specificity and increased false-positive results. Several molecular approaches are currently performed to identify circDNA in blood. Conventional methylation-specific PCR, though very sensitive method, presents high levels of false positive and negatives results and its qualitative method to interpreter the findings, limits its clinical utility\[[@B39]\]. On the other hand, methods based on quantitative methylation-specific PCR (*i.e*., MethyLight, SMART-methylation-specific PCR) offers the opportunity to select more easily the methylation thresholds and avoid false positive results identifying incomplete bisulfite conversion\[[@B40]\]. Other approaches include Methylation Array, DNA array, Surface-Enhanced Raman Scattering (SERS), and Restriction Fragment Length Polymorphism (RFLP). Another interesting and ''more digital'' methodology, called ''Methyl-BEAMing'', was demonstrated by Li et al\[[@B41]\] in order to digitally quantify cancer-derived vimentin DNA, confronting the issues with the small fraction of blood circDNA.

Given the great concerns arouse by previous approaches concerning the inability for reproducibility and high sensitivity, promising results revealed by the study of Leary et al\[[@B42]\]. The use of NGS approach showed encouraging results, distinguishing CRC patients at advanced stage from healthy controls. Thus, NGS could provide high sensitivity, covering large regions of genome for CRC early detection.

Cell-free circulating DNA-based markers
---------------------------------------

During the last two decades, circDNA has become a potential biomarker for diagnosis of malignant tumors, exhibiting their genetic and epigenetic modifications. It exists in the plasma or serum, being source of apoptotic, necrotic cancer cells or even living cells. It can appear as unbound DNA molecule; as histone part in nucleosome; or as portion of apoptotic cells. As already mentioned, there are several methods of assessing circDNA as a potential biomarker for detection of CRC at early stages. Herein, we would try to summarize the main characteristics of each method, noting presentative studies reflecting the potential clinical use of these circDNA-based modalities.

One of these methods is the quantification of circDNA levels in blood, studied thoroughly in CRC patients since the research by Leon et al\[[@B35]\] in 1977 who proved that concentration of circDNA was higher than that of healthy persons. Additional studies, such as the ones performed by Frattini, Schwarzenbach et al\[[@B43]\] respectively, verified the elevated circDNA levels in the plasma of CRC individuals compared with the non-cancerous controls\[[@B43]\]. Although, patients with malignancies may present greater levels of circDNA than normal persons, it should be emphasized that circDNA in plasma may also be observed in other clinical entities like trauma, inflammatory disorders even in healthy individuals\[[@B35]\].

In the recent years, it is well-established that the manner, with which the circDNA is released in bloodstream, reflects its size and morphology. The exact mechanism is yet to be clarified but it is believed that circDNA entered the blood by apoptosis and then it is fragmented by the action of nucleases or phagocytes, into small particles of 185 to 200 bp in length\[[@B44]\]. The measure of the ratio of long circDNA fragments to short ones mirrors circDNA integrity. A great number of studies have been performed, demonstrating inconsequent results (Table [1](#T1){ref-type="table"})\[[@B45]-[@B51]\] as concerns the sensitivity and specificity of circDNA integrity index for CRC early detection. Interestingly, a recent research by Hao et al\[[@B52]\] showed that the combination of DNA integrity index (ALU247/115 and ALU115 index) and carcinoembryonic antigen (CEA) detection may be efficient and reproducible method for early diagnosis of CRC. Therefore, larger clinical studies should be performed in order to limit the inconsistencies that circDNA integrity method exhibits.

###### 

DNA integrity index in colorectal cancer patients

  **Ref**.                               **Increased DNA integrity**   **Decreased DNA integrity**
  -------------------------------------- ----------------------------- -----------------------------
  Umetani et al\[[@B45]\], 2006          Yes                           \-
  Da Silva Filho et al\[[@B46]\], 2013   Yes                           \-
  Leszinski et al\[[@B47]\], 2014        Yes                           \-
  Mouliere et al\[[@B48]\], 2011         \-                            Yes
  Mead et al\[[@B49]\], 2011             \-                            Yes
  Mouliere et al\[[@B50]\], 2014         \-                            Yes
  Yörüker et al\[[@B51]\], 2015          \-                            Yes

Microsatellite alterations is another investigation field related to tumorigenesis of CRC and consist of MSI and LOH. Due to their presence in circDNA, it is assumed that they could be potential CRC biomarkers for early diagnosis of affected individuals. As we already have mentioned, *MSI* refers to deletions or insertions of a few nucleotides (1-6 bp in length) in genes responsible for repair during DNA replication, the MMR genes\[[@B16]\], while *LOH* analysis emphasizes the loss of chromosomal parts carrying tumor suppressor genes. These somatic alterations have been detected in blood, nearly in 35% of all CRC patients. The existence of MSI-related circDNA fragments is known since the ending of 20^th^ century followed by many studies focusing on the presence of MSI and LOH in circDNA\[[@B53]\]. One of these by Hibi et al showed in 1999 that, although *LOH* and *MSI* found in 80% CRC patients when examined their microsatellite alterations, these shifts weren't verified upon the corresponding serum-based circDNA. Therefore, the available data reveals the relatively low sensitivity and specificity in diagnosing CRC at early stages when microsatellite alterations are investigated.

Similar disappointing results have been arisen from the study of circulating mitochondrial DNA (mtDNA) as potential circDNA-based biomarker for premature diagnosis of colonic neoplasia. Mitochondria are the cornerstone in energy metabolism, aging, and apoptosis, playing a crucial role in shifting the cell from scheduled death to abnormal cell growth, thus having potential contribution to the carcinogenesis\[[@B54]\]. An important part of mtDNA is its D-loop region, a noncoding region which involves the expression and organization of the mitochondrial genome. It is hypothesized that this part of mtDNA is a hotspot of mutations leading to DNA instability, opinion that has been verified in several types of cancers such as, head and neck, colorectal, stomach, prostate, breast\[[@B55]\]. Despite the initial encouraging signs, mtDNA shows reduced detection rate of early stage CRC, as the study by Hibi et al\[[@B56]\] revealed, where the discovery of mtDNA modifications (somatic mutation in D-loop region) in tissues of early CRC patients haven't been noted in their circDNA.

As it is stated previously, the blood-based circDNA in CRC patients is composed by important molecules which have implicated in tumorigenesis process. Since 1992 when Vogelstein et al\[[@B34]\] discovered *KRAS* gene mutation in stools samples of CRC-affected individuals, high mutation frequency genes, as *KRAS*, *TP53*, and *APC* have been used as potential markers in circDNA analysis for early diagnosis of colonic malignant lesions\[[@B57],[@B58]\]. The results were discouraging due to low concentration of tumor circDNA (based on the somatic mutations analysis of *KRAS/TP53/APC* genes modification) in CRC patients compared with the wild-type circDNA in non-CRC individuals\[[@B58]\]. Moreover, it should be noted that even the use of NGS circDNA detecting method, hasn't offered any improvement in detection of these aberrant tumor DNA mutations\[[@B59]\]. Finally, as aforementioned, genes such as *APC, TP53*, and *KRAS* are mutated in a great degree of CRC cases, spreading over different parts of genome, making mutational assessment difficult. Thus, it is reasonable to assume that very large genomic regions would need to be evaluated in order to obtain a respectable sensitivity and in combination of the unique presentation of modified genes in each patient, it is still difficult enough to use somatic mutations for CRC early detection.

Abnormal DNA methylation as a cell-free circulating DNA biomarker
-----------------------------------------------------------------

As it has been already highlighted, the critical role of abnormal DNA methylation to specific steps in the CRC carcinogenesis has been expressed since 1983 from Feinberg and Vogelstein\[[@B20]\]. Since then and during the recent years, many studies have revealed that this epigenetic modification has been associated with the normal mucosa-ACF-adenoma-carcinoma sequence, playing an important role in CRC development, mainly, at early stages\[[@B22]-[@B27]\]. It is known that during DNA methylation, DNA methyl transferases (DNMTS) catalyze the addition of a methyl group (-CH3) to the fifth carbon position on cytosines within CpG dinucleotides. The latter, although spread over throughout the human genome, they are frequently discovered in the promoter regions of nearly 70% of genes, usually named as "CpG-islands"\[[@B60]\]. Furthermore, it is well-established by now that hypermethylation of tumor suppressor promoters genes could induce transcriptional gene silencing, resulting on aberrant cellular signaling and therefore potential initiation of tumorigenesis process\[[@B61]\]. Moreover, it is interesting that methylation could happen in CpG sites throughout the genomic body and not necessarily only in promoter regions leading though to transcriptional activation\[[@B62]\]. On the other hand, global hypomethylation which frequently presented prematurely during carcinogenesis, exhibits loss of DNA methylation throughout the genome, resulting on CIN and cell mutation\[[@B63]\]. Consequently, the significance of aberrant DNA methylation led to investigation and discovery of blood-based mainly, due to its noninvasiveness and cost-effectiveness, CRC detection biomarkers.

One of the most investigated genes is the *SEPT9* gene involved in cellular proliferation control. The methylation of v2 promoter region of *SEPT9* has been demonstrated in CRC biopsy lesions compared with normal tissues. According to Grützmann et al\[[@B64]\], its detection in plasma of CRC patients exhibited a sensitivity of 72% and specificity of 90%, something that was validated by the study of Warren et al\[[@B65]\]. Nevertheless, a recent prospective trial performed by Church et al\[[@B66]\] investigated the *SEPT9* methylation in 7941 asymptomatic individuals during screening with available assay showing a CRC detection rate up to 48.2% and specificity up to 91.5%. Obviously, the need of further researches upon this commercially available test is indispensable not only to improve its detection rate but also to discover new assays for *SEPT9* methylation detection. Furthermore, researchers understanding the usefulness of *SEPT9* have assessed potential combinations with other methylation biomarkers. Tänzer et al\[[@B67]\] have shown that methylated DNA from advanced premalignant intestinal lesions could be discovered using the panel of aristaless-like homeobox 4 (*ALX4*), and *SEPT9* markers. Similarly, Kostin et al\[[@B68]\] compared the methylation status of *SEPT9*, Helicase-like transcription factor (*HLTF*) and *ALX4* genes in macroscopically findings compatible with colorectal cancer (*n* = 55) and morphologically intact areas of the large bowel (*n* = 71), showing that this panel of biomarkers characterized by a sensitivity nearly to 74%-88% and a specificity 90%-96% for CRC early identification. Finally, He et al\[[@B69]\] demonstrated high sensitivities (81%-84%) and specificities (87%-90%) for noninvasive blood-based testing for initial-phase CRC, using multiplex MethyLight PCR assay to detect concomitantly, aberrant methylation pattern of *ALX4, SEPT9*, or transmembrane protein with EGF-like, and two follistatin-like domains 2 (*TMEFF2*) genes.

Apart from the aforementioned *SEPT9*-combined panels, there are recently studies showing even greater CRC detection rates if combined analysis of several genes is used. Alhquist et al\[[@B70]\] presented high overall sensitivity (87%) for the CRC detection compared with *SEPT9* (60%), using the combination of methylated genes such as bone morphogenetic protein (BMP3), N-myc downstream regulated family member 4 (NDRG4), vimentin, tissue factor pathway inhibitor-2 (TFPI2), mutant KRAS and β-actin. According to Carmona et al\[[@B71]\], there is a 78% sensitivity for CRC early diagnosis when combining angiotensin II receptor type 1 (*AGTR1*), wingless-type MMTV integration site family member 2 (*WNT2*), slit homolog 2 (Drosophila) (*SLIT2*) genes. Moreover, Cassinotti et al\[[@B72]\] exhibited the potential use of gene panel, consisting of D-type cyclin gene (*CYCD2*), hypermethylated in Cancer 1 (*HIC1*), *PAX5*, Ras association domain family 1, isoform A (*RASSF1A*), retinoblastoma tumor suppressor (*RB1*) and sheep red blood cells (SRBC) with sensitivity nearly 84% and specificity 68%. Comparable results revealed by others studies making these panels powerful tools for future large-scale trials\[[@B73]-[@B95]\] (Table [2](#T2){ref-type="table"}).

###### 

Abnormally methylated genes as potential circDNA blood-based colorectal cancer detection biomarkers

  **Potential biomarkers**                                       **CRC sensitivity (%)**   **CRC specificity (%)**   **Ref**.
  -------------------------------------------------------------- ------------------------- ------------------------- -----------------
  ALX4                                                           40-83                     70-82                     \[67,76\]
  TFPI2                                                          76-89                     \-                        \[77-80\]
  SDC2                                                           92                        \-                        \[81\]
  RUNX3                                                          65                        100                       \[82,83\]
  NEUROG1                                                        52-64                     91                        \[84\]
  MGMT                                                           39                        96                        \[74\]
  RARβ2                                                          24                        100                       \[74\]
  NGFR                                                           51                        84                        \[85\]
  9-Sep                                                          48-90                     86-93                     \[64-67,70,86\]
  TMEFF2                                                         65                        69                        \[85\]
  Vimentin                                                       59                        93                        \[41\]
  RASSF2A                                                        58                        100                       \[74\]
  Wif-1                                                          74                        98                        \[74\]
  APC                                                            6                         100                       \[87\]
  hMLH1                                                          43                        98                        \[87\]
  HTLF                                                           21-34                     98-100                    \[87,88\]
  SFRP2                                                          67                        94                        \[89\]
  CDKN2A/P16                                                     71                        100                       \[83\]
  Panel: SEPT9, HLTF and ALX4                                    74-88                     90-96                     \[68\]
  Panel: SEPT9 and ALX4                                          \-                        \-                        \[67\]
  Panel: *MGMT*, *RASSF2A*, *Wif-1* gene                         86.5                      \-                        \[74\]
  Panel: BMP3, NDRG4, vimentin, TFPI2, mutant KRAS and β-actin   87                        \-                        \[69\]
  Panel: AGTR1, WNT2, SLIT2                                      78                        \-                        \[71\]
  Panel: CINP1, FBN1, INA, SNCA, MAL and SPG20                   90-99                     \-                        \[73\]
  Panel: CYCD2, HIC1, PAX5, RASSF1A, RB1 and SRBC                84                        68                        \[72\]
  Panel: THBD and C9orf50                                        71                        80                        \[75\]
  RASSF1A, E-cadherin                                            \-                        \-                        \[72,90\]
  CAHM                                                           \-                        \-                        \[91\]
  FRP2, TPEF/HPP1                                                \-                        \-                        \[83,84,92\]

ALX4: Aristaless-like homeobox 4; TFPI2: Tissue factor pathway inhibitor 2; SDC2: Syndecan 2; RUNX3: Runt-related transcription factor 3; NEUROG1: Neurogenin 1; MGMT: O-6-methylguanine-DNAmethyltransferase; RARβ2: Retinoic acid receptor β2; NGFR: Nerve growth factor receptor; SEPT9: Septin 9; TMEFF2: Transmembrane protein with EGF-like, and two follistatin-like domains 2; RASSF2A: Ras association domain family 2 (isoform A); Wif-1: Wnt inhibitory factor-1; APC: Adenomatosis polyposis coli; hMLH1: MutL homolog 1; HTLF: Helicase-like transcription factor; SFRP2: Secreted frizzled-related protein 2; CDKN2A/P16: Cyclin-dependent kinase inhibitor 2A; BMP3: Bone morphogenetic protein; NDRG4: N-myc downstream regulated family member 4; KRAS: Kirsten rat sarcoma 2 viral oncogene homolog; AGTR1: Tissue fac angiotensin II receptor type 1; WNT2: Wingless-type MMTV integration site family member 2; SLIT2: Slit homolog 2 (Drosophila); CINP1 FBN1: Fibrillin 1; SNCA: α-synuclein gene; SPG20: Spastic paraplegia-20; CYCD2: D-type cyclin gene; HIC1: Hypermethylated in cancer 1; RASSF1A: Ras association domain family 1 (isoform A); RB1: Retinoblastoma tumor suppressor; SRBC: Sheep red blood cells; THBD: Thrombomodulin; C9orf50: Chromosome 9 open reading frame 50; FRP2: Frizzled related protein 2; TPEF/HPP1: Transmembrane protein containing epidermal growth factor, follistatin domain/hyperplastic polyposis 1.

In parallel, several blood-based methylated genes as potential biomarkers have been studied either alone or within panels as previously demonstrated, and a summary of them exhibited in Table [2](#T2){ref-type="table"}, concerning their detection rate\[[@B41],[@B64]-[@B67],[@B70],[@B72],[@B74]-[@B92]\]. Some of them (*SEPT9, ALX4, SDC2, RUNX3, TMEFF2, NEUROG1*) present high sensitivity and specificity for CRC detection during initial stages when analyzing methylation status of circDNA\[[@B67],[@B69]\]. Although the evaluation some of these aberrant methylated genes may demonstrate better diagnostic results than the *SEPT9* analysis, their cost effectiveness, further technical improvement and low testing uptake issues impede their use within large-scale clinical trials\[[@B70],[@B93]\]. Thus, *SEPT9* as the most common blood-based methylation analysis biomarker holds promising example of sending on real life the laboratory methylation studies upon circDNA, for early CRC diagnosis of average-risk individuals.

circDNA pre-analysis considerations
-----------------------------------

As we stated before, analysis of *SEPT9* gene methylation could be subject of further technical advance\[[@B93]\]. Therefore, it is reasonable to presume that several factors could play crucial role such as blood sampling and circDNA processing. It is well-established that blood-based circDNA could be extracted from both plasma and serum with the latter one exhibiting higher concentration of DNA\[[@B94],[@B95]\]. However there are studies suggesting that this high amount of DNA in serum reflects the *in vitro* lysis of leucocytes when the procedures of coagulation and/or fibrinolysis take place\[[@B95]\]. Another theory highlights the significant effect that chemicals differences between serum and plasma have during DNA extraction\[[@B96]\]. Other factors that researches should take into account are: The interval time of blood drawn and centrifugation; the sample storage modality; the anticoagulant used; temperature; and the plasma-based DNA isolation protocol\[[@B96]\]. All these parameters exhibit enormous significance as concerns the efficiency and quality of circDNA analysis, illustrating the reliability that newer methods of circDNA analysis, should have.

CONCLUSION AND FUTURE ASPIRATIONS
=================================

Colorectal cancer is one of the deadliest malignancies to date even though various techniques are available to prevent and detect its emergence. Although these preventive modalities (sigmoidoscopy, colonoscopy, FOBT, FIT) exhibit high CRC detection sensitivity and specificity, the acceptance rate among population remains low. In parallel, the rapid progression of molecular biology has revealed new translational research fields related to discovery of potential CRC biomarkers in body "liquid fluids". These markers evaluate the fragments of DNA, RNA or proteins in the blood or feces demonstrating an increasingly cost-effective and sensitive way to detect premalignant modification of genome in individuals on average risk for CRC development. Thus, with this review we tried to highlight those circDNA blood-based biomarkers that offer an easy, cost-effective and with minimal invasiveness diagnosis of colonic neoplasia (Table [2](#T2){ref-type="table"}). We believe that this research demonstrate in depth the need for further studies to be done which should be large randomized and will try to evaluate or elucidate the clinical value of all these new proposed screening tests which could be combined the older ones as a critical strategy to improve quality of the existing life expectancy as well as to advance the latter one.
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